[IL-10 serum levels in children with moderate asthma].
Levels of an interleukin 10 (IL-10) are reduced in asthmatic patients in comparison to healthy subjects. Fact, that IL-10 is produced by Th1 and that inhibits cytokine production by Th2 lymphocytes has led to the concept that IL-10 might be beneficial in mitigating allergic inflammation. The purpose of this study was to define the effect of 4 week monotherapy with triamcinolone acetonide or nedocromil sodium on the serum level of IL-10, bronchial hyperresponsiveness and clinical parameters in atopic asthma children. It was an 8 week, randomised, double-blind trial of 37 children with moderate asthma allergic to house dust mite. Patients were randomly allocated to receive 200 mcg triamcinolone twice daily (n = 18), or 0.004 g nedocromil four times daily (n = 19). Thirty children completed the study. After treatment with triamcinolone the level of IL-10 in blood serum significantly increased, bronchial hyperreactivity significantly decreased, and all clinical parameters improved. Mean IL-10 levels in serum before and after treatment with triamcinolone were 7.5 pg/ml with 95%CI 6.79%-8.22% and 14.21 pg/ml with 95%CI 11.33%-17.09% respectively (p < 0.001). After treatment with nedocromil, clinical symptoms improved significantly, IL-10 serum levels and bronchial hyperreactivity did not change significantly (p = 0.094 and p = 0.09 respectively). This study demonstrates that one possible way by which triamcinolone contribute to inhibition of inflammation is by effect on IL-10.
Stelmach
Iwona
I
Samodzielny Oddział Kliniczny Interny Dzieciecej i Alergologii I.P. AM w Łodzi.
Jerzyńska
Joanna
J
Bobrowska
Monika
M
Brzozowska
Agnieszka
A
Majak
Paweł
P
Kuna
Piotr
P
D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D002648:Child; D004311:Double-Blind Method; D004391:Dust / Q000009:adverse effects; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D017835:Nedocromil / Q000008:administration & dosage*; D012621:Seasons; D013997:Time Factors; D014221:Triamcinolone / Q000008:administration & dosage*
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D004391:Dust; D017835:Nedocromil; D016753:Interleukin-10; D014221:Triamcinolone